Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15052922 | 0.82 | — | — | |
| SCHEMBL22851680 | 0.71 | — | — | |
| SCHEMBL8029968 | 0.71 | — | — | |
| SCHEMBL8354695 | 0.67 | — | — | |
| SCHEMBL12959753 | 0.67 | — | — | |
| SCHEMBL18652824 | 0.67 | — | — | |
| SCHEMBL8950 | 0.67 | — | — | |
| SCHEMBL22122249 | 0.67 | — | — | |
| SCHEMBL15173465 | 0.66 | — | — | |
| SCHEMBL13751193 | 0.63 | PIK3CD (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-114605327-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114716381-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114573510-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-114591242-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114634447-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113636978-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-113603645-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11826351-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11471441-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-114716381-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114634447-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114621146-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114605327-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114591242-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114573510-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-108473481-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CTSK 1071/4885 |
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CTSK 1071/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CTSK 1071/4885 |
| US-11826351-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CTSK 1071/4885 |
| US-11471441-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CTSK 1071/4885 |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CTSK 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.